NCT07612046

Brief Summary

The purpose of this study is to develop a dedicated MRI scan of the pancreas (MRP) to better detect pancreatic cancer in people who are at a high risk for pancreatic cancer.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
79

participants targeted

Target at P50-P75 for all trials

Timeline
23mo left

Started May 2026

Geographic Reach
1 country

7 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress4%
May 2026May 2028

Study Start

First participant enrolled

May 20, 2026

Completed
1 day until next milestone

First Submitted

Initial submission to the registry

May 21, 2026

Completed
7 days until next milestone

First Posted

Study publicly available on registry

May 28, 2026

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 20, 2028

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 20, 2028

Last Updated

May 28, 2026

Status Verified

May 1, 2026

Enrollment Period

2 years

First QC Date

May 21, 2026

Last Update Submit

May 21, 2026

Conditions

Keywords

Pancreatic CancerPancreas CancerMemorial Sloan Kettering Cancer Center26-174

Outcome Measures

Primary Outcomes (1)

  • Compare image quality of novel high-resolution magnetic resonance pancreas (MRP) to conventional MRCP

    Develop and pilot a focused high-resolution magnetic resonance pancreas (MRP) exam to help facilitate early pancreatic cancer detection in high-risk individuals. Image quality for T1, T2, and DWI sequences performed on the novel MRP exam will be compared to conventional MRCP performed in the same participants.

    Up to 3 years

Study Arms (1)

Participants at high risk for pancreas ductal adenocarcinoma

Participants will be high-risk individuals enrolled in the Memorial Sloan Kettering Pancreatic Tumor Registry

Diagnostic Test: MRIDiagnostic Test: Endoscopic ultrasound

Interventions

MRIDIAGNOSTIC_TEST

Participants will undergo a single MRI of the abdomen without contrast

Also known as: Magnetic Resonance CholangioPancreatography, MRP
Participants at high risk for pancreas ductal adenocarcinoma
Endoscopic ultrasoundDIAGNOSTIC_TEST

EUS will be scheduled the same day or within 2 weeks prior to MRP

Also known as: EUS
Participants at high risk for pancreas ductal adenocarcinoma

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Investigators will conduct this pilot study in high-risk individuals enrolled in the Memorial Sloan Kettering Pancreatic Tumor Registry

You may qualify if:

  • Two first-degree relatives with pancreas cancer, one being a first-degree relative to the individual
  • Pathogenic mutation in APC, BRCA1, MLH1, MSH2, MSH6, PMS2, EPCAM, PALB2, or TP53 and a first/second-degree relative with pancreas cancer
  • Pathogenic mutation in CDKN2A/p16, STK11, PRSS1, SPINK1/PST1, CTRC, CPA1, ATM, or BRCA2
  • Meets surveillance age eligibility, which is typically age 50, or 10 years earlier than the youngest relative with pancreas cancer. For individuals with certain gene mutations, this can be earlier. All participants must be aged 21+
  • For this pilot MRP study, we will additionally apply the following Criteria:
  • Consents to follow-up contact
  • US residents
  • Completed MRI with MRCP with no actionable findings related to the pancreas (e.g. a pancreatic mass)
  • No metallic artifacts covering the pancreas on prior MRCP
  • Scheduled for endoscopic ultrasound
  • No new contraindications for MRI (e.g. new MR unsafe device)
  • No history of claustrophobia or use of anxiolytic on prior MRI
  • No history of abdominal surgery that may affect interpretation of either EUS or MR
  • No medical conditions that confers increased and/or unacceptable risk for anesthesia
  • We will recruit surveillance participants who had at least one prior MRCP in the last 3 years. They must also undergo a same-day EUS procedure as part of their surveillance. Nearly all active cohort participants have had at least one recent MRCP and, on average, our Registry gastroenterologist Dr. Rolston performs EUS in \~260 surveillance participants per year. Accordingly, it is highly feasible to recruit more than 79 participants in the grant period, and recruitment is constrained by budget.
  • +5 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (7)

Memorial Sloan Kettering Basking Ridge (Consent Only)

Basking Ridge, New Jersey, 07920, United States

RECRUITING

Memorial Sloan Kettering Monmouth (Consent only)

Middletown, New Jersey, 07748, United States

RECRUITING

Memorial Sloan Kettering Bergen (Consent Only)

Montvale, New Jersey, 07645, United States

RECRUITING

Memorial Sloan Kettering Suffolk-Commack (Consent only)

Commack, New York, 11725, United States

RECRUITING

Memorial Sloan Kettering Westchester (Consent only)

Harrison, New York, 10604, United States

RECRUITING

Memorial Sloan Kettering Cancer Center (All Protocol Activites)

New York, New York, 10065, United States

RECRUITING

Memorial Sloan Kettering Nassau (Consent Only)

Uniondale, New York, 11553, United States

RECRUITING

Related Links

MeSH Terms

Conditions

Pancreatic Neoplasms

Interventions

Cholangiopancreatography, Magnetic ResonanceEndosonography

Condition Hierarchy (Ancestors)

Digestive System NeoplasmsNeoplasms by SiteNeoplasmsEndocrine Gland NeoplasmsDigestive System DiseasesPancreatic DiseasesEndocrine System Diseases

Intervention Hierarchy (Ancestors)

Magnetic Resonance ImagingTomographyDiagnostic ImagingDiagnostic Techniques and ProceduresDiagnosisDiagnostic Techniques, Digestive SystemUltrasonography

Study Officials

  • Richard Kinh Gian Do, MD, PhD

    Memorial Sloan Kettering Cancer Center

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Richard Kinh Gian Do, MD, PhD

CONTACT

Mengmeng Du, ScD

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 21, 2026

First Posted

May 28, 2026

Study Start

May 20, 2026

Primary Completion (Estimated)

May 20, 2028

Study Completion (Estimated)

May 20, 2028

Last Updated

May 28, 2026

Record last verified: 2026-05

Data Sharing

IPD Sharing
Will share

• Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made following one year after publication and for up to 36 months later. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

Locations